Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

While biologic therapies have transformed IBD treatment by targeting specific immune pathways to reduce inflammation and induce remission, they carry potential risks, including rare kidney ...

Assistant Professor Yu-Hsin Chiu (邱于芯) from National Tsing Hua University (NTHU) in Taiwan and Director Hsing-Pang Hsieh (謝興邦 ...

The present study used microbiome profiling to discover possible biomarkers and molecular pathways underlying autoimmune disorders, including SLE and IBD. Researchers collected 78 fecal samples ...

Pathways increased during OV treatment included ... a four-week OV treatment led to clinical remission for 80% of PSC-IBD patients and mucosal healing in all patients. Besides, there was a ...

Major Cause of Inflammatory Bowel Disease Discovered June 5, 2024 — Researchers have discovered a new biological pathway that is a principal driver of inflammatory bowel disease (IBD ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

If the thought of having a spoonful of plastic in your noggin sounds bad to you, you’re not the only one. Scientists are ...

Microplastics, present in human brains, liver and kidneys, pose serious health risks such as oxidative stress, inflammation ...

Your gut health controls your immune system more than you think. Learn how an imbalanced gut can trigger autoimmunity and ...

Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its lead asset, FXR314.

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...